Answers are grounded in this paper and cite their sources.
Randomized trial shows longer overall survival with osimertinib in untreated EGFR-mutated NSCLC, suggesting its effectiveness.
Among patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those who received a comparator EGFR-TKI. The safety profile for osimertinib was similar to that of the comparator EGFR-TKIs, despite a longer duration of exposure in the osimertinib group. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov number, NCT02296125.).
No takes yet. Share an insight, caveat, or question.
Ramalingam et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: